MASI

ROSEN, A TOP RANKED LAW FIRM, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation – MASI

Retrieved on: 
Giovedì, Maggio 9, 2024
Class Action Lawsuit, Professional Services, Legal, Titan, Masimo, News, Advertising, Justice minister, Security (finance), Justice, Form 10-Q, DOJ, MASI, False Claims Act, Cryptocurrency

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24978 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24978 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Masimo to Present in BofA Securities Health Care Conference

Retrieved on: 
Mercoledì, Maggio 8, 2024
Biotechnology, Pharmaceutical, Hardware, General Health, Health, Medical Devices, Health Technology, Technology, MASI, Conference, Webcast

Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities Health Care Conference on Wednesday, May 15, 2024 at 4:20 p.m. Pacific Time.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities Health Care Conference on Wednesday, May 15, 2024 at 4:20 p.m. Pacific Time.
  • A live webcast of the presentation will be available on the Masimo website at www.masimo.com .
  • A replay of the webcast will be available following the live presentation.

Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System

Retrieved on: 
Lunedì, Maggio 6, 2024
Technology, FDA, Baby, Maternity, Public Relations, Investor Relations, Communications, Audio, Video, General Health, Consumer, Health, Consumer Electronics, NICU, Humidity, Hospital, Skin, OTC, Depression, Oxygen saturation (medicine), PR, Parent, Infant, Motion, Skin temperature, Perfusion, Science, Incidence, Patient, QHD, Caregiver, Multimedia, MASI, Child, Diagnosis, Retinopathy, Temperature, Medical device

Alongside the FDA clearance, Masimo will make Stork’s new alarm features available to all existing and new Stork users through the Masimo Stork App, in an update scheduled to be released this summer.

Key Points: 
  • Alongside the FDA clearance, Masimo will make Stork’s new alarm features available to all existing and new Stork users through the Masimo Stork App, in an update scheduled to be released this summer.
  • Masimo Stork is 510(k) cleared for OTC use as a wearable device intended for the monitoring of multiple physiological parameters.
  • Masimo Stork is not intended to replace the monitoring, diagnosis, or treatment provided by a physician or healthcare provider.
  • Masimo Stork is not intended for use with infants and neonates previously diagnosed with cardiovascular or respiratory disease or conditions.

Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7

Retrieved on: 
Martedì, Aprile 23, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MASI, ID

Masimo (NASDAQ: MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • Masimo (NASDAQ: MASI) will release first quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, May 7, 2024.
  • The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m.
  • ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.
  • Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number.

Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile

Retrieved on: 
Martedì, Aprile 16, 2024
Technology, Medical Devices, Hospitals, Clinical Trials, Health Technology, Biotechnology, Hardware, Pharmaceutical, Health, Artificial Intelligence, FDA, Risk, AI, Halo, Patient safety, Patient, Caregiver, MASI, Medical device

Masimo (NASDAQ: MASI) today announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety.
  • Kiani’s speech, “Empowering Patient Safety Through AI,” will discuss how artificial intelligence-based technologies, by analyzing both historical and immediate data, can help clinicians prevent errors of omission, improving patient safety, patient outcomes, and clinician efficiency.
  • We’re proud to be at the forefront of this very promising avenue of improving patient safety and patient care.
  • At Masimo, we have always championed patient safety, and we’re particularly excited to collaborate with caregivers around the world to advance patient safety using AI.”
    For more information about the Global Ministerial Summit, please visit psschile.minsal.cl .

MASIMO ALERT: Bragar Eagel & Squire, P.C. is Investigating Masimo Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Venerdì, Marzo 22, 2024
Telephone, MASI, Defendant, P.C, Class, Fraud, Cryptocurrency

Our investigation concerns whether the board of directors of Masimo have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Masimo have breached their fiduciary duties to the company.
  • Masimo’s stock price fell in response to the corrective event on July 17, 2023, as alleged supra.
  • In particular, on July 17, 2023, Masimo reduced the lower end of full year revenue guidance for the healthcare business to $1.30 billion from $1.45 billion.
  • The Company also announced a reduction in annual revenue guidance for the non-healthcare business to $800 million to $850 million from $965 million to $995 million.

Masimo Responds to Politan Capital’s Nomination of Director Candidates and Refutes Politan’s False Claims

Retrieved on: 
Lunedì, Aprile 1, 2024
Cardiology, Biometrics, Telemedicine, Virtual Medicine, Health, Medical Devices, Consumer Electronics, Health Technology, Technology, CFO, Committee, MASI, Patient, Human, Audit committee, Bank statement, IP, Compensated emancipation, COGS, The Wall Street Journal, Annual general meeting, Management

Masimo (NASDAQ: MASI) today confirmed that Politan Capital Management LP (“Politan”) has provided notice of its intent to nominate two candidates to stand for election to the Masimo Board of Directors at the company’s 2024 Annual Meeting.

Key Points: 
  • Masimo (NASDAQ: MASI) today confirmed that Politan Capital Management LP (“Politan”) has provided notice of its intent to nominate two candidates to stand for election to the Masimo Board of Directors at the company’s 2024 Annual Meeting.
  • The facts undermine Mr. Koffey’s arguments and expose his willingness to mislead stockholders in pursuit of control of Masimo.
  • A list of some of the documents and information Mr. Koffey has been provided is attached as Exhibit A.
  • A list of the members of senior management Mr. Koffey has had discussions with is attached as Exhibit B.

Politan Nominates Two Independent Candidates for Masimo Board

Retrieved on: 
Lunedì, Marzo 25, 2024
Banking, Professional Services, Finance, Analytical chemistry, Biophysical environment, Health, Lead, Doctor of Philosophy, IP, M&A, Audit committee, Corporate spin-off, Audit, WHEN, WILL, Science, MASI, Stryker Corporation, Laboratory, Dentsply Sirona, Compensated emancipation, Common stock, Financial management, Knowledge, Broadcom Inc., Acquisition, Security (finance), Senior, INC, Avient Corporation, Annual general meeting, Separation, WALL, MIT, Common, Hope College, Stanford University, National academy, Government, COGS, Management

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Key Points: 
  • Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
  • Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated:
    “When shareholders overwhelmingly elected Michelle Brennan and me to the Masimo Board last year, we were optimistic we could work productively with the rest of the Board to drive positive change.
  • However, at this stage the Board has been provided zero details, and Politan has serious concerns given the lack of basic governance and oversight we have observed since joining the Board.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito, William Jellison and Darlene Solomon (collectively, the “Participants”).

Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business

Retrieved on: 
Venerdì, Marzo 22, 2024
Hardware, General Health, Health, Medical Devices, Consumer Electronics, Health Technology, Wearables, Mobile Technology, Technology, MASI, Century, Security (finance)

Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business.
  • The Board and management will evaluate the proposed structure of the separation.
  • Masimo expects that the separation will include its consumer audio and consumer health products, including the Stork baby monitor and the Freedom smart watch and band.
  • I proposed a separation of the consumer business in January and the Board has agreed to move forward.

Masimo Named One of Fast Company’s Most Innovative Companies in North America

Retrieved on: 
Martedì, Marzo 19, 2024
Medical Devices, Health, Technology, Other Technology, Health Technology, General Health, Perl, Medicine, MASI, Patient, Hospital, Pulse, Multimedia, Approximation error, FDA, Opioid overdose

Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, is thrilled to announce its recognition as one of Fast Company’s Most Innovative Companies in North America for 2024.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, is thrilled to announce its recognition as one of Fast Company’s Most Innovative Companies in North America for 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240319317729/en/
    Masimo is one of Fast Company's Most Innovative Companies in North America for 2024.
  • (Graphic: Business Wire)
    “We are honored to be recognized by Fast Company as one of the top 10 Most Innovative Companies in North America for 2024,” said Joe Kiani, Founder and CEO of Masimo.
  • Masimo has been recognized as one of the 10 most innovative organizations in the North America sector, a testament to its leadership in advancing patient care through cutting-edge and innovative solutions.